Bruno Stefania, Herrera Sanchez Maria Beatriz, Pasquino Chiara, Tapparo Marta, Cedrino Massimo, Tetta Ciro, Camussi Giovanni
Department of Medical Sciences, University of Torino, Torino, Italy.
Molecular Biotechnology Centre, University of Torino, Torino, Italy.
Stem Cells Int. 2019 Jun 2;2019:6351091. doi: 10.1155/2019/6351091. eCollection 2019.
Cell therapy may be regarded as a feasible alternative to whole organ transplantation to treat end-stage liver diseases. Human liver stem cells (HLSCs) are a population of cells easily obtainable and expandable from a human adult liver biopsy. HLSCs share with mesenchymal stromal cells the same phenotype, gene expression profile, and differentiation capabilities. In addition, HLSCs show a specific commitment to the hepatic phenotype. Injection of HLSCs into immunodeficient mice fed with a methionine-choline-deficient diet to induce nonalcoholic steatohepatitis ameliorates liver function and morphology. In particular, HLSC treatment induced a reduction of liver fibrosis and inflammation at morphological and molecular levels. Moreover, HLSCs were able to persist for up to 3 weeks after the injection. In conclusion, HLSCs have healing effects in a model of chronic liver disease.
细胞疗法可被视为治疗终末期肝病的全器官移植的一种可行替代方案。人肝干细胞（HLSCs）是一类易于从成人肝脏活检组织中获取并扩增的细胞群体。HLSCs与间充质基质细胞具有相同的表型、基因表达谱和分化能力。此外，HLSCs表现出对肝表型的特定趋向性。将HLSCs注射到喂食蛋氨酸-胆碱缺乏饮食以诱导非酒精性脂肪性肝炎的免疫缺陷小鼠体内，可改善肝功能和形态。特别是，HLSC治疗在形态和分子水平上诱导肝纤维化和炎症减轻。此外，HLSCs在注射后能够持续存在长达3周。总之，HLSCs在慢性肝病模型中具有治疗作用。
